NextCure (NXTC)
(Delayed Data from NSDQ)
$5.78 USD
+0.03 (0.60%)
Updated Sep 25, 2025 03:38 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NXTC 5.78 +0.03(0.60%)
Will NXTC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NXTC based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for NXTC
Is NXTC showing upside potential? Boomer Buy Setup shows up after climbing 3.9%
Technical picture remains unchanged for NXTC after it falls 0.54% on September 24
NXTC forms 20 Day Moving Average Support on September 22
Is NXTC set to rally? Upper Bollinger Band Walk shows up after declining 0.29%
NXTC forms Upper Bollinger Band Walk on September 18